These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 8269208

  • 1. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty.
    Ellis SG, Tcheng JE, Navetta FI, Muller DW, Weisman HF, Smith C, Anderson KM, Califf RM, Topol EJ.
    Coron Artery Dis; 1993 Feb; 4(2):167-75. PubMed ID: 8269208
    [Abstract] [Full Text] [Related]

  • 2. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study.
    Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ.
    J Am Coll Cardiol; 1993 Aug; 22(2):381-9. PubMed ID: 8335808
    [Abstract] [Full Text] [Related]

  • 3. Blockade of the human platelet GPIIb/IIIa receptor by a murine monoclonal antibody Fab fragment (7E3): potent dose-dependent inhibition of platelet function.
    Bhattacharya S, Jordan R, Machin S, Senior R, Mackie I, Smith CR, Schaible TF, Weisman HF, Lahiri A.
    Cardiovasc Drugs Ther; 1995 Oct; 9(5):665-75. PubMed ID: 8573549
    [Abstract] [Full Text] [Related]

  • 4. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty.
    Konstantopoulos K, Kamat SG, Schafer AI, Bañez EI, Jordan R, Kleiman NS, Hellums JD.
    Circulation; 1995 Mar 01; 91(5):1427-31. PubMed ID: 7867183
    [Abstract] [Full Text] [Related]

  • 5. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
    EPIC Investigators.
    N Engl J Med; 1994 Apr 07; 330(14):956-61. PubMed ID: 8121459
    [Abstract] [Full Text] [Related]

  • 6. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.
    Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ.
    Circulation; 1994 Oct 07; 90(4):1757-64. PubMed ID: 7923659
    [Abstract] [Full Text] [Related]

  • 7. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
    Turner NA, Moake JL, Kamat SG, Schafer AI, Kleiman NS, Jordan R, McIntire LV.
    Circulation; 1995 Mar 01; 91(5):1354-62. PubMed ID: 7867173
    [Abstract] [Full Text] [Related]

  • 8. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
    Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF.
    J Am Coll Cardiol; 1995 Dec 01; 26(7):1665-71. PubMed ID: 7594101
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
    Mascelli MA, Kleiman NS, Marciniak SJ, Damaraju L, Weisman HF, Jordan RE.
    Am Heart J; 2000 Apr 01; 139(4):696-703. PubMed ID: 10740154
    [Abstract] [Full Text] [Related]

  • 10. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
    Lincoff AM, Tcheng JE, Califf RM, Bass T, Popma JJ, Teirstein PS, Kleiman NS, Hattel LJ, Anderson HV, Ferguson JJ, Cabot CF, Anderson KM, Berdan LG, Musco MH, Weisman HF, Topol EJ.
    Am J Cardiol; 1997 Feb 01; 79(3):286-91. PubMed ID: 9036746
    [Abstract] [Full Text] [Related]

  • 11. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ, Satler LF.
    J Invasive Cardiol; 1994 Feb 01; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty.
    Akkerhuis KM, van Den Brand MJ, van Der Zwaan C, Peels HO, Suryapranata H, van Der Wieken LR, Stibbe J, Hoffmann J, Baardman T, Deckers JW, Simoons ML.
    Heart; 2001 Apr 01; 85(4):444-50. PubMed ID: 11250974
    [Abstract] [Full Text] [Related]

  • 13. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.
    Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff AM, Tcheng JE, Sigmon KN, Joseph D, Rios G, Trainor K, Rose D.
    Am J Cardiol; 1995 Dec 15; 76(17):1222-7. PubMed ID: 7503000
    [Abstract] [Full Text] [Related]

  • 14. A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty.
    Bates ER, McGillem MJ, Mickelson JK, Pitt B, Mancini GB.
    Circulation; 1991 Dec 15; 84(6):2463-9. PubMed ID: 1659954
    [Abstract] [Full Text] [Related]

  • 15. Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty.
    Mazurov AV, Pevzner DV, Antonova OA, Byzova TV, Khaspekova SG, Semenov AV, Vlasik TN, Samko AN, Staroverov II, Ruda MY.
    Platelets; 2002 Dec 15; 13(8):465-77. PubMed ID: 12487780
    [Abstract] [Full Text] [Related]

  • 16. ABCIXIMAB: a new antiaggregant used in angioplasty.
    Genetta TB, Mauro VF.
    Ann Pharmacother; 1996 Mar 15; 30(3):251-7. PubMed ID: 8833561
    [Abstract] [Full Text] [Related]

  • 17. Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty.
    Byrne A, Moran N, Maher M, Walsh N, Crean P, Fitzgerald DJ.
    Arterioscler Thromb Vasc Biol; 1997 Nov 15; 17(11):3224-9. PubMed ID: 9409315
    [Abstract] [Full Text] [Related]

  • 18. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
    Kereiakes DJ, Kleiman N, Ferguson JJ, Runyon JP, Broderick TM, Higby NA, Martin LH, Hantsbarger G, McDonald S, Anders RJ.
    Circulation; 1997 Aug 19; 96(4):1117-21. PubMed ID: 9286938
    [Abstract] [Full Text] [Related]

  • 19. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.
    Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V, Sax FL.
    J Am Coll Cardiol; 1996 Mar 01; 27(3):536-42. PubMed ID: 8606262
    [Abstract] [Full Text] [Related]

  • 20. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB, Grines CL, Bittl JA, Becker RC, Kereiakes DJ, Gilchrist IC, Clegg J, Stankowski JE, Grogan DR, Harrington RA, Emanuelsson H, Weaver WD.
    Am Heart J; 2006 Mar 01; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.